Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06958536

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Crohn's Disease Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Investigational Site Number: 0360002, Brisbane, Queensland, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening
  • Confirmed diagnosis of moderate-to-severe CD
  • History of prior exposure to standard treatment (5-Amino Salicylates (5-ASAs), steroids, immunomodulators or antibiotics) or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
  • On stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, Azathioprine (AZA), 6-Mercaptopurine (6-MP), or Methotrexate (MTX), or Antibiotics, etc.)
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion criteria

  • Participants with active Ulcerative Colitis (UC), indeterminate colitis, adenomatous colonic polyps not excised, colonic mucosal dysplasia (low- or high-grade dysplasia) or short bowel syndrome
  • Participants with CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement
  • Participants with following ongoing known complications of CD:
  • Any manifestation that might require bowel surgery while enrolled in the study
  • Participant with ostomy or ileoanal pouch
  • Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short bowel syndrome
  • Participant with surgical bowel resection within the past three months prior to screening, or a history of >3 bowel resections
  • History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

SAR442970

Drug

Route of Administration: Subcutaneous

Placebo

Drug

Route of Administration: Subcutaneous

Primary outcomes

  1. Percentage of participants who achieve endoscopic response at Week 16

    Time frame: From Baseline to Week 16

    Endoscopic response is defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) >50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading. The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.

Secondary outcomes

  1. Percentage of participants who achieve clinical remission based on Crohn's Disease Activity Index (CDAI) at Week 16

    Time frame: At Week 16

    CDAI clinical remission is defined as CDAI score <150. CDAI is a composite instrument that includes participant symptoms evaluated over 7 days (abdominal pain, stool frequency and general well-being), as well as presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. These items are scored individually, weighted, and do not contribute equally to the overall score. The CDAI is derived from summing up the weighted individual scores of eight items. CDAI approximately ranges from 0 to 600 with higher scores indicating more severe disease.

  2. Percentage of participants who achieve PRO-2 (Patient Reported Outcome) clinical remission at Week 16

    Time frame: At Week 16

    PRO-2 clinical remission is defined as using the average daily Stool Frequency (SF) ≤3 and not worse than baseline and average daily AP ≤1 and not worse than baseline.

  3. Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 16

    Time frame: At Week 16

    Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore >1 in any individual variable based on central reading.

  4. Percentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 16

    Time frame: At Week 16

    CDAI clinical remission is defined as CDAI score <150, endoscopic response is defined as a decrease in SES-CD >50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

  5. Percentage of participants who achieve CDAI clinical response at Week 16

    Time frame: At Week 16

    CDAI clinical response is defined as reduction of CDAI ≥100 points from baseline.

  6. Change from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) score

    Time frame: From Baseline to Week 16

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item instrument assessing health-related quality of life in IBD patients across four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Each question evaluates experiences over the previous two weeks on a 7-point Likert scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224, with higher scores indicating better quality of life. Both domain-specific and overall scores can be calculated.

  7. Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score

    Time frame: From Baseline to Week 16

    The FACIT-F questionnaire assesses fatigue associated with anemia through 13 fatigue-related questions. Each item is scored on a 5-point Likert scale (0="not at all" to 4="very much"), with total scores ranging from 0 to 52. High scores represent less fatigue. For Crohn's Disease patients, a 7-10 point improvement on the FACIT-F total score may represent meaningful improvements.

  8. On-treatment serum concentrations of SAR442970 at predefined timepoints

    Time frame: Up to End of Study (approximately 164 weeks)

  9. Number and percentage of participants with any Treatment Emergent Adverse Events (TEAEs) during induction, maintenance and Long-term Extension (LTE) treatment period

    Time frame: Up to End of Study (approximately 164 weeks)

  10. Number and percentage of participants with any TEAEs during open-label treatment period

    Time frame: Up to Week 52

  11. Incidence of Anti-drug Antibodies (ADAs) over time

    Time frame: Up to End of Study (approximately 164 weeks)

  12. Percentage of participants who achieve endoscopic remission based on centrally read SES-CD at Week 52

    Time frame: At Week 52

    Endoscopic remission is defined as SES-CD ≤4 and at least 2 point reduction versus baseline and no subscore >1 in any individual variable based on central reading.

  13. Percentage of participants achieving CDAI clinical remission at Week 52

    Time frame: At Week 52

    CDAI clinical remission is defined as CDAI <150.

  14. Percentage of participants achieving CDAI clinical remission at both Week 16 and at Week 52

    Time frame: At Week 52

    CDAI clinical remission is defined as CDAI <150.

  15. Percentage of participants who achieve endoscopic response at Week 52

    Time frame: At Week 52

    Endoscopic response is defined as decrease in SES-CD >50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

  16. Percentage of participants who achieve endoscopic response at both Week 16 and Week 52

    Time frame: At Week 52

    Endoscopic response is defined as decrease in SES-CD >50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

  17. Percentage of participants who achieve CDAI clinical response at Week 52

    Time frame: At Week 52

    CDAI clinical response is defined as reduction of CDAI ≥100 points from baseline.

  18. Percentage of participants who achieve both clinical remission based on CDAI score and endoscopic response based on SES- CD at Week 52

    Time frame: At Week 52

    CDAI clinical remission is defined as CDAI score <150, endoscopic response is defined as a decrease in SES-CD >50% from baseline (or a decrease of at least 2 points for subjects with a baseline score of 4 or more and isolated ileal disease) based on central reading.

Study contacts

Contact information is provided by the study sponsor or research team.

Trial Transparency email recommended (Toll free for US & Canada)

CONTACT

[email protected]

800-633-1610 ext. Option 6

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease

Acronym: CHROMA CD

Important dates

Study start
2025
Primary completion
2026
Study completion
2029
First posted
May 6, 2025
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.